Understanding how cancer cells affect T cell activation in kidney cancer
Metabolic barriers to T cell activation in clear cell renal cell carcinoma
This study is looking at how clear cell kidney cancer affects the immune system's T cells, which help fight cancer, by changing the way cancer cells use sugar and other nutrients, and it hopes to find new ways to boost T cell activity for better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11061783 on NIH RePORTER |
What this research studies
This research investigates how clear cell renal cell carcinoma (ccRCC) affects the activation of T cells, which are crucial for the immune response against cancer. The study focuses on the metabolic barriers that cancer cells create, particularly how they manipulate glucose and glutamine levels in the tumor microenvironment to suppress T cell function. By analyzing tumor-infiltrating lymphocytes from patients, the researchers aim to identify specific metabolic pathways that hinder T cell activity, potentially leading to new therapeutic strategies that enhance anti-tumor immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with clear cell renal cell carcinoma who are undergoing surgical treatment.
Not a fit: Patients with other types of kidney cancer or those who do not have clear cell renal cell carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for patients with clear cell renal cell carcinoma.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways to enhance T cell responses in cancer, indicating that this approach may yield significant insights.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Rathmell, Jeffrey C. — Vanderbilt University Medical Center
- Study coordinator: Rathmell, Jeffrey C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.